Literature DB >> 25545329

Activity-associated effect of LDL receptor missense variants located in the cysteine-rich repeats.

A Etxebarria1, A Benito-Vicente1, M Stef2, H Ostolaza1, L Palacios2, C Martin3.   

Abstract

BACKGROUND: The LDL receptor (LDLR) is a Class I transmembrane protein critical for the clearance of cholesterol-containing lipoprotein particles. The N-terminal domain of the LDLR harbours the ligand-binding domain consisting of seven cysteine-rich repeats of approximately 40 amino acids each. Mutations in the LDLR binding domain may result in loss of receptor activity leading to familial hypercholesterolemia (FH). In this study the activity of six mutations located in the cysteine-rich repeats of the LDLR has been investigated.
METHODS: CHO-ldlA7 transfected cells with six different LDLR mutations have been used to analyse in vitro LDLR expression, lipoprotein binding and uptake. Immunoblotting of cell extracts, flow cytometry and confocal microscopy have been performed to determine the effects of these mutations. In silico analysis was also performed to predict the mutation effect. RESULTS AND
CONCLUSION: From the six mutations, p.Arg257Trp turned out to be a non-pathogenic LDLR variant whereas p.Cys116Arg, p.Asp168Asn, p.Asp172Asn, p.Arg300Gly and p.Asp301Gly were classified as binding-defective LDLR variants whose effect is not as severe as null allele mutations.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Familial hypercholesterolemia; LDLR; Ligand binding domain; Mutation class defect; Mutations

Mesh:

Substances:

Year:  2014        PMID: 25545329     DOI: 10.1016/j.atherosclerosis.2014.12.026

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

1.  Genomic Sequencing for Newborn Screening: Results of the NC NEXUS Project.

Authors:  Tamara S Roman; Stephanie B Crowley; Myra I Roche; Ann Katherine M Foreman; Julianne M O'Daniel; Bryce A Seifert; Kristy Lee; Alicia Brandt; Chelsea Gustafson; Daniela M DeCristo; Natasha T Strande; Lori Ramkissoon; Laura V Milko; Phillips Owen; Sayanty Roy; Mai Xiong; Ryan S Paquin; Rita M Butterfield; Megan A Lewis; Katherine J Souris; Donald B Bailey; Christine Rini; Jessica K Booker; Bradford C Powell; Karen E Weck; Cynthia M Powell; Jonathan S Berg
Journal:  Am J Hum Genet       Date:  2020-08-26       Impact factor: 11.025

2.  The UCL low-density lipoprotein receptor gene variant database: pathogenicity update.

Authors:  Sarah Leigh; Marta Futema; Ros Whittall; Alison Taylor-Beadling; Maggie Williams; Johan T den Dunnen; Steve E Humphries
Journal:  J Med Genet       Date:  2016-11-07       Impact factor: 6.318

Review 3.  Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants.

Authors:  Asier Benito-Vicente; Kepa B Uribe; Shifa Jebari; Unai Galicia-Garcia; Helena Ostolaza; Cesar Martin
Journal:  Int J Mol Sci       Date:  2018-06-05       Impact factor: 5.923

4.  Therapeutic targets of hypercholesterolemia: HMGCR and LDLR.

Authors:  Shizhan Ma; Wenxiu Sun; Ling Gao; Shudong Liu
Journal:  Diabetes Metab Syndr Obes       Date:  2019-08-21       Impact factor: 3.168

5.  Mutation type classification and pathogenicity assignment of sixteen missense variants located in the EGF-precursor homology domain of the LDLR.

Authors:  Unai Galicia-Garcia; Asier Benito-Vicente; Kepa B Uribe; Shifa Jebari; Asier Larrea-Sebal; Rocio Alonso-Estrada; Joseba Aguilo-Arce; Helena Ostolaza; Lourdes Palacios; Cesar Martin
Journal:  Sci Rep       Date:  2020-02-03       Impact factor: 4.379

6.  Replacement of cysteine at position 46 in the first cysteine-rich repeat of the LDL receptor impairs apolipoprotein recognition.

Authors:  A Benito-Vicente; K B Uribe; H Siddiqi; S Jebari; U Galicia-Garcia; A Larrea-Sebal; A Cenarro; M Stef; H Ostolaza; F Civeira; L Palacios; C Martin
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

Review 7.  Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease.

Authors:  Asier Benito-Vicente; Kepa B Uribe; Shifa Jebari; Unai Galicia-Garcia; Helena Ostolaza; Cesar Martin
Journal:  Int J Mol Sci       Date:  2018-11-01       Impact factor: 5.923

8.  Molecular Genetic Approach and Evaluation of Cardiovascular Events in Patients with Clinical Familial Hypercholesterolemia Phenotype from Romania.

Authors:  Cristiana-Elena Vlad; Liliana Georgeta Foia; Roxana Popescu; Ioana Popa; Ruxandra Aanicai; Delia Reurean-Pintilei; Vasilica Toma; Laura Florea; Mehmet Kanbay; Adrian Covic
Journal:  J Clin Med       Date:  2021-03-31       Impact factor: 4.964

9.  Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemia: A case report.

Authors:  Ane Bayona; Francisco Arrieta; Carmen Rodríguez-Jiménez; Francisco Cerrato; Sonia Rodríguez-Nóvoa; Milagros Fernández-Lucas; Diego Gómez-Coronado; Pedro Mata
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.